Genetic factors account for up to 80% of the liability for schizophrenia and bipolar disorder. Genome-wide association studies (GWAS) have successfully identified several single nucleotide polymorphisms (SNPs) and genes associated with increased risk for both disorders. Single SNP analyses alone do not address the overall genomic or polygenic architecture of psychiatric disorders as the amount of phenotypic variation explained by each GWAS-supported SNP is small whereas the number of SNPs/regions underlying risk for illness is thought to be very large. The polygenic risk score models the aggregate effect of alleles associated with disease status present in each individual and allows us to utilise the power of large GWAS to be applied robustly in small samples. Here we make the case that risk prediction, intervention and personalised medicine can only benefit with the inclusion of polygenic risk scores in imaging genetics research.
Psychiatric disorders are highly heritable, especially schizophrenia and bipolar disorder. Heritability is the proportion of trait variation that is accounted for by genetic factors, as opposed to trait variation due to environmental factors. Twin and family studies for schizophrenia have placed heritability around 0.8 (Lichtenstein et al., 2009; Sullivan et al., 2003) and between 0.6-0.85 for bipolar disorder (Craddock and Sklar, 2009; McGuffin et al., 2003) . After the human genome was first sequenced the genetics field has produced huge technological strides towards estimating heredity (Lander et al., 2001) . The most common genetic marker is the single nucleotide polymorphism (SNP), a single subunit change in the DNA sequence. SNPs are located on a DNA chip, which is used to create a genetic profile for each individual. In turn DNA chips are used in genome-wide associations studies (GWAS) that estimate the heritability of a disorder throughout the genome by comparing healthy controls with patients, in a hypothesis-free way. The first disease upon which the GWAS technique was used was agerelated macular degeneration in 2005 (Klein et al., 2005) , and since then many genes have been implicated in macular degeneration (Fritsche et al., 2013) .
After the first GWAS studies in schizophrenia it soon became apparent there were no common variants that had a large influence on risk, but rather that there were thousands of variants of very small effect that together acted to increase or reduce risk. The first signs of success in schizophrenia started to emerge in 2008 with a GWAS study that implicated the ZNF804A gene . In 2009, the SGENE consortium (Stefansson et al., 2009) and the International Schizophrenia Consortium (Shi et al., 2009 ) published papers on other variants associated with the schizophrenia. These groups then combined their efforts and began publishing under the Psychiatric Genomics Consortium banner with papers in 2011, detailing five variants, and 2013, with 13 variants (Ripke et al., , 2013 . However, real progress began when the sample size exceeded 15,000 cases, with an inflection point being reached where, instead of discovering one variant every couple of thousand cases, variants began to be discovered every time approximately another 250 cases and 250 controls were added to the sample size. In other words, once the size of the sample had increased to >15,000 cases, the power to detect variants reached a point where GWAS could detect the effects of the modest size at which a large number of schizophrenia-associated variants are operating.
Then, in 2014, Ripke and colleagues (Ripke et al., 2014) published 108 regions associated with the risk of schizophrenia. In this analysis that included over 36,989 patients and 113,075 healthy controls, few if any candidate genes replicated; for example COMT, a gene implicated in the risk of schizophrenia and extensively used in imaging genetics had a p-value of 0.56 (Ripke et al., 2014) . The same was true for the BDNF gene, with a p-value of 0.006. Interestingly the BDNF gene is significantly associated with smoking and obesity (Hallden et al., 2013) , attributes with increased prevalence in schizophrenia (Hennekens et al., 2005) . Other genes that had not been identified from previous schizophrenia studies were identified in the Psychiatric Genomics Consortium (PGC2) paper and showed significant association with schizophrenia, such as the DRD2, a target for antipsychotic drugs, and the GRM3 involved in glutamatergic transmission (Ripke et al., 2014) .
Although genetic research in bipolar disorder is less published upon than in schizophrenia, susceptibility genes for bipolar disorder have also been identified through GWAS (Alsabban et al., 2013) . The most robustly associated SNPs are located in the CACNA1C (Ferreira et al., 2008; Sklar et al., 2008 Sklar et al., , 2011 , the ITIH3 (Sklar et al., 2011) , the TRANK1 , the NCAN (Cichon et al., 2011) , the ANK3 (Athanasiu et al., 2010; Ferreira et al., 2008; Schulze et al., 2009; Scott et al., 2009; Sklar et al., 2008; Smith et al., 2009; Tesli et al., 2011) , the SYNE1 (Green et al., 2013; Sklar et al., 2011) and the ODZ4 gene (Sklar et al., 2011) .
The question that arises is how to utilise the predictive power of GWAS findings. The predictive power of genetic risk prediction is not yet useful for clinical applications but where genetic prediction may have utility is in acting as a biomarker for schizophrenia and bipolar disorder traits within individuals in, e.g. imaging studies. A key hypothesised benefit of brain imaging approaches is their ability to decipher if and how genetic risk factors impact brain structure and function, especially in brain regions associated with disease expression.
In the last decade a substantial amount of literature has focused on the effect of candidate genes on brain structure and function. Most of these studies have used single gene variants and risk haplotypes that were found traditionally from linkage studies and more recently from GWAS studies. Rasetti and Weinberger (2011) reviewed the literature of candidate genes in schizophrenia in functional magnetic resonance imaging (fMRI) studies, indexed by cognitive task. In the working memory (WM) domain: (a) the GAD1, GRM3, COMT, RGS4, CACNA1C, KCNH2, DTNBP1 and MTHFR genes have shown to impact function of the dorso-lateral prefrontal cortex (DLPFC), (b) the COMT, PRODH and RGS4 have been associated with altered engagement of the ventrolateral prefrontal cortex (VLPFC), (c) the PRODH with parietal lobe function, (d) the NRG1, G72 and DISC1 with hippocampal function and last (e) the DRD2 and COMT with supragenual anterior cingulate gyrus (ACC) function. In the cognitive control domain: (a) the DTNBP1, DRD2 and MAOA have been associated with DLPFC function, (b) the DRD2 with VLPFC function, (c) the DRD2 and MAOA with parietal lobe function and (d) the COMT, DRD2 and MAOA with ACC function.
From all these genes the only ones replicated or discovered in GWAS studies are GRM3, CACNA1C and DRD2 (Ripke et al., 2014) . The CACNA1C (Paulus et al., 2014) and ZNF804A GWAS schizophrenia risk SNPs were found to be correlated with reduced prefrontal-hippocampal coupling during WM tasks in healthy controls and schizophrenia patients. Tan et al. (2012) using dynamic causal modelling (Friston et al., 2003) on fMRI WM data in healthy participants differentiated the effects of the COMT, DRD2 and AKT1 genes on the prefrontalparietal WM maintenance and prefrontal-striatal WM manipulation network. Specifically, the prefrontal-parietal circuit is influenced only by the COMT gene, while the prefrontal-striatal circuit populated by the dopamine D2 receptors is affected by all three genes.
Most imaging genetics studies in bipolar disorder have focused on the effect of the CACNA1C risk gene, a bipolar disorder GWAS gene, on structural and functional neuroimaging data, in order to better understand the contribution of genetics to bipolar disorder. Two structural studies have found increased grey matter volume (Kempton et al., 2009 ) and increased total cortical volume (Wang et al., 2011) associated with the risk CACNA1C variant. Perrier et al. (2011) using a regions of interest approach found increased grey matter density in the right amygdala and hypothalamus in participants with the risk CACNA1C SNP, while another study found that the CACNA1C gene influences the brainstem rather than grey matter volume (Franke et al., 2010) .
Studies on the effect of the CACNA1C gene on brain function that included bipolar disorder patients, have found increased right amygdala activity during a negative emotional faces task in CACNA1C risk carriers (Jogia et al., 2011; Tesli et al., 2013) . In another study, during an episodic memory task, carrying the CACNA1C risk variant resulted in a stronger decrease of hippocampal and ACC activation in bipolar disorder relatives, indicating an additive effect of CACNA1C variation on familial risk (Erk et al., 2013) . Using Dynamic causal modeling (DCM) connectivity analysis, two studies found that during emotional processing, the presence of the CACNA1C risk allele was associated with decreased outflow of information from the medial frontal gyrus (Radua et al., 2013) and decreased visual-prefrontal effective connectivity (Dima et al., 2013) . In both studies the findings were significantly more marked in patients than in their unaffected relatives and healthy controls. Although all these GWAS candidate genes imaging genetics studies illustrate the potential usefulness of genetic imaging, single SNP analyses alone do not address the overall genomic or polygenic architecture of schizophrenia and bipolar disorder.
Polygenic scores
A typical GWAS tests millions of SNPs for association with the disease of choice, but this necessitates the application of a very conservative significance threshold, usually 5×10 −8 for multiple testing correction. Nevertheless, the amount of phenotypic variation explained by each GWAS-supported SNP is very small whereas the number of SNPs underlying the risk for illness is thought to be very large (Purcell et al., 2009) . For that reason, candidate genes studies have to be treated with caution since the possibility of a single SNP explaining a large variance of the disease expression is slim, whether this is in behavioural, cognitive or neuroimaging traits.
By utilising the vast amount data created by GWAS studies (current sample size in schizophrenia >150,000) we can calculate the polygenic risk score (PRS) for each individual associated with a specific disorder, e.g. schizophrenia or bipolar disorder. A PRS incorporates information from both GWAS-SNPs and SNPs that are not genome-wide significant. These non-significant genome-wide GWAS SNPs are meeting nominal significance criteria, even though it is accepted that some of them are false positives. The PRS thus models the aggregate effect of SNPs (alleles) associated with disease status present in each individual and allows us to utilise the power of large GWAS to be applied robustly in small samples (Dudbridge, 2013; Ferreira et al., 2008; Purcell et al., 2009; Sklar et al., 2011) . For example, the variance explained by the current schizophrenia PRS is 18%, while the variance explained by the CACNA1C gene is around 0.3% (Ripke et al., 2014) . In Figure 1 we show that only with a sample size of 5,000 we have 100% power to detect the impact of the CACNA1C gene. With the statistical power of the PRS being exponentially better than that of a single SNP it points to a paradigm shift in the field of imaging genetics.
The first application of the PRS method was in schizophrenia, a study that supported the polygenic component of schizophrenia and its similarities with bipolar disorder (Purcell et al., 2009 ). These results were replicated in a second larger sample that doubled the proportion of variance explained by common variants to 6% in schizophrenia . The polygenic model has also been successfully used in other traits like the body mass index (BMI; Speliotes et al., 2010) , where the BMI PRS has shown positive association with disease expression (Peterson et al., 2011) . Furthermore, the PRS method has been used successfully for the association of personality traits and mood disorders (Luciano et al., 2012; Middeldorp et al., 2011) , depression and anxiety (Demirkan et al., 2011) and the five major psychiatric disorders (Cross-Disorder Group of the Psychiatric Genomics Consortium; Genetic Risk Outcome of Psychosis (GROUP) Consortium, 2013). It has also been used to differentiate genetically, for example, schizophrenia and autism (Vorstman et al., 2013) or schizophrenia and intelligence (van Scheltinga et al., 2013) . The schizophrenia PRS has been correlated with quantitative measures of psychosis in terms of symptoms scales (Derks et al., 2012) and neuroimaging measures (Walton et al., 2013) . Specifically the PRS for schizophrenia was associated positively with reduced left DLPFC during a WM processing paradigm (Walton et al., 2013) .
Recently, the bipolar disorder PRS has been used to examine its relationship with brain function and structure in individuals with familial risk for a mood disorder (Whalley et al., 2012 (Whalley et al., , 2013 . Whalley et al. (2012) showed a positive correlation between bipolar disorder PRS and activation of the ACC, amygdala and other limbic regions of the brain, areas that have been impaired in bipolar disorder expression. In the same cohort, the bipolar disorder PRS was significantly associated with decreased white matter integrity in the right superior longitudinal fasciculus (Whalley et al., 2013) . Lastly, a study found an association between the PRS for major depressive disorder and reduced cortical thickness in the left amygdala-medial prefrontal circuitry in healthy young adults (Holmes et al., 2012) .
Clinical relevance
Where does the PRS fit in clinical practice? In a large Swedish population-based study research showed that adding a PRS on a prediction model for prostate biopsies, would cut the biopsies from 12% to 5%, while missing < 1% of the aggressive cancers in the population (Aly et al., 2011) . Array genotyping in patients has advantages that other biological tests currently lack: it is cheap, easy to analyse and, most importantly stays stable throughout the lifespan of someone life. As sample sizes increase exponentially in the field of psychiatry one can assume that more genetic risk variants will be identified in the near future, thus adding to the usefulness of genetic profiles substantially. The hope is that polygenic scoring, especially in common diseases that seem to be affected by a large number of genes with small effects sizes, as is the case with schizophrenia and bipolar disorder, will lead to personalised medicine. Personalised genetics information is hopefully going to lead from interventional medicine to preventive medicine, which will help cut down health care costs.
Another area of medicine where genetic information can influence greatly is pharmacogenomics, by keeping in mind that around 100,000 people die each year in the USA due to adverse drug reactions (Lazarou et al., 1998) and despite efforts to improve patient safety in the past few years it has not been successful (Landrigan et al., 2010; Phillips and Barker, 2010) . Although until now there have been no robust findings of common genetic variants associated to drug response that could be translated in clinical practice in psychiatry, the road has been paved for the identification of genetic determinants to personalised psychiatric treatment (Kato and Serretti, 2010; Kim et al., 2006; Kirchheiner et al., 2005; Mrazek and Lerman, 2011; Tansey et al., 2012) . The efficacy of polygenic models for risk prediction, intervention and personalised medicine can only benefit with the inclusion of other traditional risk factors such as family history and age of onset (Chatterjee et al., 2013) .
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